Asahi Kasei Pharma Corporation (AKP), headquartered in Tokyo, Japan, is a fully integrated pharmaceutical company with capabilities in R&D, manufacturing and commercialization. AKP has successfully partnered with large and small organizations to develop and commercialize a variety of innovative treatments including Famvir, Flivas, Toledomin, Xiaflex, Reclast and Kevzara as well as our own original products such as Teribone and Recomodulin. AKP has a well-established record of managing clinical trials and successfully obtaining product marketing approvals in Japan.
AKP is currently pursuing attractive new in-licensing and research collaboration opportunities in the following therapeutic areas.
- Area of Interests: Pain management, Musculoskeletal disorders, Autoimmune diseases, Critical care medicine, and Rare diseases.